Nanoencapsulation & Targeted Therapy Platform

About Fulgent Genetics

Fulgent Genetics has evolved from a genetic testing pioneer into a diversified precision medicine company, combining a comprehensive diagnostic business with an emerging therapeutic development arm. Its foundational technology platform supports an extensive menu of over 18,000 tests, including whole genome sequencing and rare disease panels, processed through a network of six accredited U.S. laboratories. The company's strategic direction involves merging diagnostic insights with therapeutic development, particularly in oncology, to create a closed-loop precision medicine model. Recent acquisitions, like Bako Diagnostics and StrataDx, further expand its capabilities in anatomic pathology and dermatopathology.

Therapeutic Areas